Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...
Travere Therapeutics (TVTX) is back in focus after the U.S. FDA approved FILSPARI as the first and only therapy for focal segmental glomerulosclerosis in certain adults and children, thereby expanding ...
Travere Therapeutics, Inc. is rated a Buy, secured full FDA approval for Filspari in FSGS, and driving a 37% stock surge.
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...
The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis ...
Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce ...
Travere Therapeutics (TVTX) stock and Ligand Pharmaceuticals (LGND) stock gain on FDA label expansion for Filspari. Read more ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...
Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results